Vical (VICL) Reports Q4 Loss of $0.03/Share

Go back to Vical (VICL) Reports Q4 Loss of $0.03/Share

Vical Reports Fourth Quarter 2015 Financial Results

March 14, 2016 6:30 AM EDT

Futility Analyses Completed on CMV Phase 3 Trial in HCT Patients and Trial Continuing as Planned

Phase 1 Trial Initiated for Novel Antifungal

SAN DIEGO, March 14, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the three and twelve months ended December 31, 2015. Net loss for the fourth quarter of 2015 was $2.4 million, or $0.03 per share, compared with a net loss of $4.6 million, or $0.05 per share, for the fourth quarter of 2014. Revenues for the fourth quarter of 2015 were $6.8 million,... More